Everything Investors Need to Know About Biogen's FDA Meeting Tomorrow

It's finally time for the Food and Drug Administration's committee of outside experts to decide on aducanumab, Biogen's (NASDAQ: BIIB) controversial drug for Alzheimer's disease.

Recent events have put shares on a roller coaster. The ride culminated with a 44% spike yesterday after the FDA posted its briefing documents for tomorrow's meeting.

Continue reading

Source Fool.com